Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.
Nearly a quarter of those taking a higher dose of Ocaliva saw an improvement in liver scarring.
The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...
Madrigal Pharmaceuticals is the latest company to enter into what’s becoming a crowded market.
Analysts say the market will reach $35 billion in the next few years.
As pharmaceutical companies race to develop treatments for NASH, they find one thing is missing: willing test subjects.
The market for therapies to treat the condition could reach as much as $35 billion dollars over the coming years.
There are currently no approved treatments for this slow, silent liver disease that may affect up to 15 million Americans.
The FDA has approved Intercept Pharmaceuticals’ Ocaliva to treat primary biliary cholangitis, previously known as primary biliary cirrhosis.
The drug has been shown to help reduce markers of liver inflammation and fibrosis, as well as increase insulin sensitivity.
An advanced version of this ’silent’ disorder affects an estimated 6.5M adults in the U.S. and Europe.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.